Clinical Trial

/Clinical Trial

ESMO 2016 NET News

Clinical benefit demonstrated with everolimus and pasireotide LAR alone or in combination in the first randomised, prospective study entirely dedicated to advanced lung and thymic carcinoids. In patients with advanced [...]

By | 2018-05-07T18:28:12+00:00 October 13th, 2016|Clinical Trial, News, Treatment News|Comments Off on ESMO 2016 NET News

New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors Not yet [...]

By | 2018-05-07T18:28:13+00:00 June 5th, 2016|Clinical Trial|Comments Off on New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors